GARS1 and Parkinson disease: For example, SPS with anti-GlyRs, the most common in patients with PERM,[14,15] always has the clinical feature of parkinsonism.[7] GlyRsare expressed in various regions of the basal ganglia.[16] Piquet et al[7] speculated that GlyRsform another inhibitory mechanism that regulates the function of the basal ganglia, which would explain the manifestation of parkinsonism in SPS patients.